VolitionRx Limited (OTC: VNRX) is a life sciences company developing blood-based diagnostic tests for different cancers. These tests are based on Nucleosomics, the practice of identifying and measuring nucleosomes in the bloodstream—an indication that cancer is present. The company aims to make the tests as common and simple to use as existing diabetic and cholesterol blood tests and is focused on bringing its diagnostic products to market first in Europe, then in the U.S., and ultimately, worldwide. For more information, visit the company’s website at www.volitionrx.com.